The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome
Open accessAbstract
Significance: This paper provides unique insights into mechanism-based therapeutics for Rett syndrome (RTT), a devastating neurodevelopmental disorder. This clinical trial was based on pioneer preclinical work from the laboratory of M.S. Outcome measures include clinical instruments, standardized behavioral measures, and biomarkers, the latter being not only objective but also applicable to experimental studies. We believe this work will a have major impact on the understanding and treatment of RTT, as well as other neurodevelopmental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the committee on methods of clinical examination in electroencephalography
(1958) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(58)90053-1 · Cited by 2,717
Reversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230 · cited 1×
“Substantial reversal of mouse model neurologic phenotypes by genetic manipulations, at different developmental stages (7, 8), has supported the testing of several candidate drugs (4, 9).”
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
A Wearable Sensor for Unobtrusive, Long-Term Assessment of Electrodermal Activity
Poh, M.-Z., Swenson, N. C., & Picard, R. W. (2010) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2009.2038487 · Cited by 693
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593 · cited 4×
“The most compelling data supporting IGF-1 as a treatment for RTT come from two studies demonstrating that systemic administration of either full length IGF-1 or its active peptide fragment reverses, at least partially, many RTT-relevant features in Mecp2-deficient mice (13, 14).”
InfluentialSelf-citationClinical manifestations and stages of rett syndrome
Hagberg, B. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10020 · Cited by 416
Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
A Comparison of the Electroencephalogram between Institutionalized and Community Children in Romania
Marshall, P. J., Fox, N. A., & Group, B. C. (2004) · Journal of Cognitive Neuroscience · doi:10.1162/0898929042304723 · Cited by 268
Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249 · cited 1×
“In fragile X syndrome, mGluR5 antagonists (43) and GABA-B agonists (44) had similarly selective effects in human trials, but were preceded by a more generalized reversal of the phenotype in preclinical studies (45, 46).”
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome
Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., Mellios, N., Tropea, D., & Sur, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311685111 · Cited by 242
Self-citationMorphological and functional reversal of phenotypes in a mouse model of Rett syndrome
Robinson, L., Guy, J., McKay, L., Brockett, E., Spike, R. C., Selfridge, J., De Sousa, D., Merusi, C., Riedel, G., Bird, A., et al. (2012) · Brain · doi:10.1093/brain/aws096 · Cited by 157
Rett syndrome diagnostic criteria: Lessons from the Natural History Study
Percy, A. K., Neul, J. L., Glaze, D. G., Motil, K. J., Skinner, S. A., Khwaja, O., Lee, H., Lane, J. B., Barrish, J. O., Annese, F., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22154 · Cited by 144
Self-citationCorvin, A. P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D. W., & Tropea, D. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.029 · Cited by 57
Makkonen, I., Kokki, H., Kuikka, J., Turpeinen, U., & Riikonen, R. (2011) · Neuropediatrics · doi:10.1055/s-0031-1291242 · Cited by 37
Cited by
Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders
Sahin, M., & Sur, M. (2015) · Science · doi:10.1126/science.aab3897 · Cited by 295
Self-citationMellios, N., Feldman, D. A., Sheridan, S. D., Ip, J. P. K., Kwok, S., Amoah, S. K., Rosen, B., Rodriguez, B. A., Crawford, B., Swaminathan, R., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.86 · Cited by 292
Self-citationSignalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome
Castro, J., Garcia, R. I., Kwok, S., Banerjee, A., Petravicz, J., Woodson, J., Mellios, N., Tropea, D., & Sur, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311685111 · Cited by 242
Self-citationModeling non-syndromic autism and the impact of TRPC6 disruption in human neurons
Griesi-Oliveira, K., Acab, A., Gupta, A. R., Sunaga, D. Y., Chailangkarn, T., Nicol, X., Nunez, Y., Walker, M. F., Murdoch, J. D., Sanders, S. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.141 · Cited by 236
Metadata
- Authors
- Khwaja, O. S., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., Nelson, C. A., Vogel-Farley, V., DeGregorio, G., Holm, I. A., Khatwa, U., Kapur, K., Alexander, M. E., Finnegan, D. M., Cantwell, N. G., Walco, A. C., Rappaport, L., Gregas, M., Fichorova, R. N., Shannon, M. W., Sur, M., & Kaufmann, W. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-03-12
- Volume
- 111
- Issue
- 12
- Pages
- 4596-4601
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2109555365
- Cited by
- 209
- References
- 15
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.